Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
4,784
Views
34
CrossRef citations to date
0
Altmetric
Research Article

Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study

Wencheng Zhanga Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Cihui Yanb Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Tian Zhanga Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Xi Chena Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Jie Dongc Department of Nutrition Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Jingjing Zhaoa Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Dong Hana Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Jun Wangd Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, ChinaView further author information
,
Gang Zhaoe Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Fuliang Caof Department of Endoscopy Diagnosis and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Dejun Zhouf Department of Endoscopy Diagnosis and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Hongjing Jiangg Department of Esophageal Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Peng Tangg Department of Esophageal Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Lujun Zhaoa Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Zhiyong Yuana Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaView further author information
,
Quanren Wangh Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang, ChinaView further author information
,
Ping Wanga Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaCorrespondence[email protected]
View further author information
&
Qingsong Panga Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3576-6909View further author information
ORCID Icon show all
Article: 1971418 | Received 31 May 2021, Accepted 16 Aug 2021, Published online: 28 Sep 2021

Citations (34)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Yanan Duan, Wenru Qin, Linlin Yang, Bing Zou, Wenting Qie, Ruiting Song, Lu Xue & Linlin Wang. (2023) Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer. Cancer Management and Research 15, pages 55-65.
Read now
Wei Zhang, Min Chen, Qingming Xiang, Shaoxing Sun, Hong Cao, Conghua Xie & Hui Qiu. (2023) Boosting the Abscopal Effect with Chemoradiotherapy/Immunotherapy Combination in Metastatic Cervical Cancer: A Case Report. Immunotherapy 15:15, pages 1239-1247.
Read now
Julie Le Naour, Zsofia Sztupinszki, Vincent Carbonnier, Odile Casiraghi, Virginie Marty, Lorenzo Galluzzi, Zoltan Szallasi, Guido Kroemer & Erika Vacchelli. (2022) A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients. OncoImmunology 11:1.
Read now
Cihui Yan, Xiaoxue Ma, Zhoubo Guo, Xiaoying Wei, Dong Han, Tian Zhang, Xi Chen, Fuliang Cao, Jie Dong, Gang Zhao, Xuan Gao, Tao Wang, Yao Jiang, Ping Wang, Qingsong Pang & Wencheng Zhang. (2022) Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade. OncoImmunology 11:1.
Read now

Articles from other publishers (30)

Paweł Cisek, Aleksander Strąk, Paulina Stachyra-Strawa, Andrzej Majdan & Ludmiła Grzybowska-Szatkowska. (2024) The Role of Brachytherapy Alone and in Combined Treatment of Esophageal Cancer—A Review. Applied Sciences 14:7, pages 2840.
Crossref
Jiang-Qiong Huang, Huan-Wei Liang, Yang Liu, Long Chen, Su Pei, Bin-Bin Yu & Xin-Bin Pan. (2024) Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Frontiers in Immunology 15.
Crossref
Weijia Zhang, Min Zhu, Ying Xiang, Yujiao Sun, Shuang Li, Jun Cai & Hai Zeng. (2024) Current and future perspectives in unresectable locally advanced esophageal squamous cell cancer (Review). Oncology Reports 51:5.
Crossref
. (2024) Expert consensus on radiotherapy combined with immunotherapy for esophageal cancer (2024 edition). Radiation Medicine and Protection.
Crossref
Hui-min Lian, Jia-liang Wu, Wei-jian Liufu, Tian-tian Yu, Shao-qing Niu, Yong Bao & Fang Peng. (2024) Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study. Cancer Immunology, Immunotherapy 73:3.
Crossref
Renxian Xie, Qingxin Cai, Tong Chen, Hongxin Huang & Chuangzhen Chen. (2024) Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma. Frontiers in Oncology 14.
Crossref
Xiaoyan Lv, Yajing Wu, Qihui Li, Chen Zheng, Qiang Lin, Qingsong Pang, Min Zhao, Jiandong Zhang & Jun Wang. (2024) Treatment-related pneumonitis after thoracic radiotherapy/chemoradiotherapy combined with anti-PD-1 monoclonal antibodies in advanced esophageal squamous cell carcinoma. Strahlentherapie und Onkologie.
Crossref
Congrong Yang, Jun Wang & Shuanghu Yuan. (2023) Chinese clinical practice guidelines for the prevention and treatment of radiation‐induced esophagitis. Precision Radiation Oncology 7:4, pages 225-236.
Crossref
Wei Deng, Xiao Chang, Xin Dong, Yuting Zhao, Dan Yang, Leilei Jiang, Anhui Shi, Huiming Yu, Rong Yu, Zefen Xiao & Weihu Wang. (2023) Induction immunochemotherapy followed by radiotherapy for patients with unresectable locally advanced or metastatic esophageal cancer: A propensity score-matched analysis. International Immunopharmacology 124, pages 110955.
Crossref
Yan Kang, Hongchao Zhen, Nina Ma, Hong Zhao & Bangwei Cao. (2023) Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature. Journal of Cancer Research and Clinical Oncology 149:17, pages 16239-16246.
Crossref
Yicong Chen, Ruixuan Yu & Yongmei Liu. (2023) Combine radiotherapy and immunotherapy in esophageal squamous cell carcinoma. Critical Reviews in Oncology/Hematology 190, pages 104115.
Crossref
Xiao-Han Zhao, Hong-Mei Gao, Jing-Yuan Wen, He-Song Wang, Luan-Ying Wu, Chun-Yang Song, Wen-Zhao Deng, Shu-Chai Zhu & Wen-Bin Shen. (2023) Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma. Discover Oncology 14:1.
Crossref
Lingbo An, Mingyang Li & Qingge Jia. (2023) Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma. Molecular Cancer 22:1.
Crossref
Mengjie Jiang, Yujie Hu, Gang Lin, Chao Chen & Huafeng Li. (2023) Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions. Frontiers in Immunology 14.
Crossref
Cihui Yan, Hui Huang, Zhunhao Zheng, Xiaoxue Ma, Gang Zhao, Tian Zhang, Xi Chen, Fuliang Cao, Hui Wei, Jie Dong, Peng Tang, Hongjing Jiang, Meng Wang, Ping Wang, Qingsong Pang & Wencheng Zhang. (2023) Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer. Frontiers in Immunology 14.
Crossref
Yujia Zhu, Jing Wen, Qiaoqiao Li, Baoqing Chen, Lei Zhao, Shiliang Liu, Yadi Yang, Sifen Wang, Yingxin Lv, Jibin Li, Li Zhang, Yonghong Hu, Mengzhong Liu & Mian Xi. (2023) Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. The Lancet Oncology 24:4, pages 371-382.
Crossref
Ugo Testa, Germana Castelli & Elvira Pelosi. (2023) The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies. Current Oncology 30:1, pages 610-640.
Crossref
Xiaoyue Wu, Yanqi Li, Kunning Zhang, Zhoubo Guo, Yang Li, Fangdong Zhao, Tian Zhang, Xi Chen, Hui Wei, Wencheng Zhang, Ping Wang & Qingsong Pang. (2023) Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study. Clinical and Translational Radiation Oncology 38, pages 130-137.
Crossref
Yang Yang, Li Zhu, Yan Cheng, Zhichao Liu, Xiaoyue Cai, Jinchen Shao, Ming Zhang, Jun Liu, Yifeng Sun, Yin Li, Jun Yi, Bentong Yu, Hongjing Jiang, Hezhong Chen, Hong Yang, Lijie Tan & Zhigang Li. (2022) Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study). BMC Cancer 22:1.
Crossref
Tongzhen Xu, Yunsong Liu, Xiaotong Lu & Jun Liang. (2022) Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review. Frontiers in Immunology 13.
Crossref
Ruixi Wang, Shiliang Liu, Baoqing Chen & Mian Xi. (2022) Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Cancers 14:20, pages 5168.
Crossref
Huiru Dai, Minling Liu, Xueying Li, Tingwei Li, Wensheng Huang, Jiehao Liao, Yun Li & Shuo Fang. (2022) A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer. World Journal of Surgical Oncology 20:1.
Crossref
Xin-Cheng Mao, Chun-Cheng Yang, Ya-Fei Yang, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Yu-Chuan Yan, Zhao-Ru Dong, Dong-Xu Wang & Tao Li. (2022) Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Frontiers in Immunology 13.
Crossref
Chenyu Wang, Linzhi Jin, Xinyu Cheng, Runchuan Ren, Anping Zheng, Anlin Hao, Nengchao Wang, Jinwen Zhang, Fuyou Zhou & Yaowen Zhang. (2022) Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study. BioMed Research International 2022, pages 1-9.
Crossref
Jing Wu, Rong Deng, Tingting Ni, Qin Zhong, Fei Tang, Yan Li & Yu Zhang. (2022) Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis. Frontiers in Oncology 12.
Crossref
Fei Chen, Lingdong Qiu, Yushu Mu, Shibin Sun, Yulong Yuan, Pan Shang, Bo Ji & Qifei Wang. (2022) Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma. Frontiers in Surgery 9.
Crossref
Yujin Qiao, Cong Zhao, Xiangnan Li, Jia Zhao, Qi Huang, Zheng Ding, Yan Zhang, Jia Jiao, Guoqing Zhang & Song Zhao. (2022) Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy. Frontiers in Immunology 13.
Crossref
Rong Qiu, Wenxi Wang, Juan Li & Yuxiang Wang. (2022) Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma. Molecular Biology Reports 49:7, pages 6633-6645.
Crossref
Xiaoxue Ma, Zhoubo Guo, Xiaoying Wei, Gang Zhao, Dong Han, Tian Zhang, Xi Chen, Fuliang Cao, Jie Dong, Lujun Zhao, Zhiyong Yuan, Ping Wang, Qingsong Pang, Cihui Yan & Wencheng Zhang. (2022) Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade. Frontiers in Immunology 12.
Crossref
Carlos Jiménez-Cortegana, Vanessa Klapp, Norma Bloy, Claudia Galassi, Ai Sato, Takahiro Yamazaki, Aitziber Buqué, Lorenzo Galluzzi & Giulia Petroni. 2022. Radiation Oncology and Radiotherapy Part A. Radiation Oncology and Radiotherapy Part A 1 16 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.